Hosted on MSN3mon
Vittoria Biotherapeutics Launches Trial for Innovative T Cell Lymphoma Therapy
VIPER-101 is built on Vittoria’s proprietary Senza5™ platform, which integrates CD5 gene-editing technology with a rapid five-day manufacturing process. This platform is designed to enhance ...
Hosted on MSN3mon
Vittoria Biotherapeutics Showcases Advancements in T Cell Therapies at 66th ASH Annual Meeting
The company’s oral and poster presentations will focus on enhancing engineered T cell therapies by targeting the CD5 pathway, a key regulator of T cell functionality. The Senza5™ platform ...
Morningstar8d
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
Engineered to target the CD5 marker—which is highly expressed on T‑cell lymphomas—GCC2005 co‑expresses a chimeric antigen receptor (CAR) alongside interleukin‑15 (IL‑15). This dual ...
Taiwan News8d
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
The ongoing Phase 1 trial (ClinicalTrials.gov Identifier: NCT06699771) will enroll up to approximately 48 patients diagnosed with relapsed or refractory NK and T‑cell malignancies. The primary ...